SUPRAX

Compare SUPRAX  to:
Compare
Compare
SUPRAX (Cefixime) 400mg tablets by Lupin Pharmaceuticals

Generic Name for SUPRAX

Cefixime 400mg; tabs.

Legal Classification:

Rx

Pharmacological Class for SUPRAX

Cephalosporin.

Manufacturer of SUPRAX

Lupin Pharmaceuticals, Inc.

Indications for SUPRAX

Susceptible infections, including pharyngitis, tonsillitis, acute bronchitis, acute exacerbation of chronic bronchitis; uncomplicated UTIs and cervical or urethral gonorrhea.

Adult dose for SUPRAX

400mg once daily or 200mg every 12 hrs. Gonorrhea: 400mg once. Renal impairment: CrCl 21–59mL/min: reduce dose by ¼; CrCl<20mL/min or dialysis: reduce dose by ½.

Children's dosing for SUPRAX

<6 months: not recommended. <50kg and 6 months–12yrs: 8mg/kg once daily or 4mg/kg every 12 hrs. >50kg or >12yrs: use adult dose. Renal impairment: CrCl 21–59mL/min: reduce dose by ¼; CrCl<20mL/min or dialysis: reduce dose by ½.

Also:

Precautions for SUPRAX

Penicillin or other allergy. Renal impairment. History of GI disease. Labor and delivery. Pregnancy (Cat.B). Nursing mothers.

Interactions for SUPRAX

May potentiate carbamazepine, anticoagulants (eg, warfarin) (monitor). May cause false (+) Clinitest, direct Coomb's, nitroprusside test for ketones. Potentiated by probenecid.

Adverse Reactions for SUPRAX

GI upset, rash, drug fever, pruritus, headache, dizziness, transient renal and hepatic effects, seizures.

How is SUPRAX supplied?

Tabs—50, 100
Susp 100mg/5mL—50mL, 75mL, 100mL
200mg/5mL—25mL, 37.5mL, 50mL, 75mL, 100mL

Related Disease:

Bronchitis, chronic
Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.